APLMNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as APLMW
Apollomics Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 24, 2026
$22.05+0.95 (+4.49%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2023 Ended Jun 30, 2023 | Sep 28, 2023 | During market hours | – | – | – |
Press releases
Announcements Apollomics filed with the SEC
Apollomics Announces $10 Million Private Placement Transaction
EX-99.1 to Form 6-K
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
EX-99.1 to Form 6-K
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value
EX-99.1 to Form 6-K
Apollomics Inc. Announces $2.0 Million Bridge Financing
EX-99.1 to Form 6-K
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
Apollomics Reports First Half 2025 Financial Results
EX-99.3 to Form 6-K
FOSTER CITY, CA, UNITED STATES, November 19, 2025
EX-99.1 to Form 6-K
its Board of Directors and Composition of Committees
EX-99.1 to Form 6-K
Listing on The Nasdaq Stock
EX-99.1 to Form 6-K
Your publication date and time will appear here. | Source: Apollomics Inc.
EX-99.1 to Form 6-K
Apollomics Announces Receipt of Nasdaq
EX-99.1 to Form 6-K
the Cayman Islands as an exempted company with limited liability)
EX-99.1 to Form 6-K
Apollomics Announces Top-line Results for Phase 3 Bridging Trial
EX-99.1 to Form 6-K
Apollomics Regains Compliance with Nasdaqs Minimum Bid Price Requirement
EX-99.1 to Form 6-K
(incorporated in the Cayman Islands with limited liability)
EX-99.1 to Form 6-K
INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
Apollomics Granted 180-Day Extension to Regain Compliance with
EX-99.1 to Form 6-K
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
EX-99.1 to Form 6-K
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
EX-99.1 to Form 6-K
INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
Apollomics, a Company Developing Novel Oncology Therapies to
EX-99.1 to Form 6-K